Nouvelles formes lipidiques de l’amphotéricine B. Revue de la littérature

Andrès, Emmanuel; Tiphine, M; Letscher-Bru, Valérie; Herbrecht, Raoul

doi:10.1016/s0248-8663(00)00304-0

Cited by 17 publications

(5 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To better understand the interactions between AmB and living cells, it is important to understand how AmB interacts with lipids, including the arrangement of AmB in lipid–sterol environments (Matsumori et al 2006 ; Gagoś and Arczewska 2010 ), the function of fungal cell walls, and the effects of AmB aggregation in biological systems (Barwicz et al 1992 ; Barwicz and Tancrede 1997 ). Only a full understanding of these phenomena can lead to the design of forms of AmB with lower toxicity and greater efficacy (Bolard et al 1980b ; Bolard and Cheron 1982 ; Paquet et al 2002 ; Matsuoka and Murata 2003 ; Sternal et al 2004 ; Gabrielska et al 2006 ; Hac-Wydro and Dynarowicz-Łątka 2006 ; Foglia et al 2011 ), not only by appropriate formulation (Brogden et al 1998 ; Andres et al 2001 ; Hac-Wydro et al 2005c ; Menez et al 2006 ; Moen et al 2009 ; Hamill 2013 ; Pham et al 2013 ) but also by molecular modification (Hac-Wydro et al 2005c ; Paquet and Carreira 2006 ; Czub et al 2009 ; Croatt and Carreira 2011 ; Tevyashova et al 2013 ; Wilcock et al 2012 , 2013 ). For instance, toxicity can be reduced by using appropriate cationic derivatives of AmB (Slisz et al 2004 ).…”

Section: Introductionmentioning

confidence: 99%

Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments

2014

View full text Add to dashboard Cite

In the past decade substantial progress has been made in understanding the organization and biological activity of amphotericin B (AmB) in the presence of sterols in lipid environments. This review concentrates mainly on interactions of AmB with lipids and sterols, AmB channel formation in membranes, AmB aggregation, AmB modifications important for understanding its biological activity, and AmB models explaining its mechanism of action. Most of the reviewed studies concern monolayers at the water–gas interface, monolayers deposited on a solid substrate by use of the Langmuir–Blodgett technique, micelles, vesicles, and multi-bilayers. Liposomal AmB formulations and drug delivery are intentionally omitted, because several reviews dedicated to this subject are already available.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments

2014

View full text Add to dashboard Cite

show abstract

“…To reduce the toxic effects, AmB has been formulated with lipids to allow the infusion of higher doses of AmB with less toxicity to mammalian cells. Several AmB liposomal preparations have been developed, including Amphotec (Amphocil), Abelcet, and AmBisome 4–6. These lipid formulations present lower toxicity as compared to Fungizone®; and can be administered to patients at doses up to 5 mg/kg/day.…”

Section: Introductionmentioning

confidence: 99%

Galactomannan–amphotericin B conjugate: synthesis and biological activity

Farber

Ickowicz

Sionov

et al. 2010

Polymers for Advanced Techs

View full text Add to dashboard Cite

Polysaccharide conjugated amphotericin B (AmB) was synthesized by conjugation of AmB to oxidized galactomannan (GM) by reductive amination and tested for antifungal activity. AmB conjugates were investigated for their ability to inhibit Candida albicans growth. Antifungal efficiency of the synthetic AmB-GM depends on both, AmB content and duration of exposure. The most potent compound was a conjugate which contains 40% AmB with minimal inhibition concentration of 0.25 mg/l. In vitro toxicity analysis revealed that conjugates with 20, 30, and 40% w/w AmB content have no hemolytic effect and no influence on the viability of the VERO kidney cells. Furthermore, maximal tolerant dose (MTD) of the conjugate was determined in vivo and found to be 60 mg/kg (equivalent to AmB), while commercial Fungizone 1 demonstrated increased toxicity of 3 mg/kg on mice model.

show abstract

“…Several AmB liposomal preparations have been developed, including Amphotec (Amphocil), Abelcet, and AmBisome [33][34][35]. Table 2 summarizes the properties of the AmB formulations.…”

Section: Amb Formulations Approved For Human Usementioning

confidence: 99%

New Formulations and Derivatives of Amphotericin B for Treatment of Leishmaniasis

Golenser¹,

Domb

2006

MRMC

View full text Add to dashboard Cite

The clinical treatment of leishmaniasis is based on a limited number of drugs, which are associated with adverse effects and have already induced resistance. Amphotericin B (AmB), a polyene antibiotic produced by Streptomyces sp, is the only anti-leishmanial drug which has not induced clinical resistance since its discovery in 1956. The limiting factor in the use of AmB is its toxic effects, mainly nephrotoxicity. The maximal dose of AmB for human use is 1.5 mg/kg which sometimes is not sufficient for cure. The mode of action of AmB is associated with its toxicity: it selectively binds to parasite membrane ergosterol but also, to a lesser extent, to human cholesterol. Apart from this mechanism, AmB has immunomodulatory effects, some of them are deleterious. Reduction of the toxic effects by using lipid formulations allows the infusion of higher doses of AmB. Unfortunately, these formulations are relatively expensive and therefore out of reach for patients in need, in the endemic areas. All the existing formulations are given parenterally, which has obvious disadvantages; most important is the need for hospitalization or multiple visits in the clinic. The current efforts to improve AmB are directed at the production of AmB aggregates in liquid solutions, encapsulation with lipid components, and solubilization by binding to soluble polymers. The expected improved treatment resulting from use of the new formulations is based on better pharmacokinetics, reduced toxicity originating from slow release, targeting to the infected organ and an altered pattern of immune responses (related to AmB). Of particular importance are the attempts to produce derivatives for oral treatment, which will decrease costs of hospitalization and improve applicability for children and the elderly population.

show abstract

Nouvelles formes lipidiques de l’amphotéricine B. Revue de la littérature

Cited by 17 publications

References 69 publications

Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments

Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments

Galactomannan–amphotericin B conjugate: synthesis and biological activity

New Formulations and Derivatives of Amphotericin B for Treatment of Leishmaniasis

Contact Info

Product

Resources

About